Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; Student Research Committee, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
DS & CI Research Group, Universitas Sumatera Utara, Medan, Indonesia.
Life Sci. 2021 Dec 1;286:120047. doi: 10.1016/j.lfs.2021.120047. Epub 2021 Oct 13.
Due to its high occurrence and mortality rate, breast cancer has been studied from various aspects as one of the cancer field's hot topics in the last decade. Epigenetic alterations are spoused to be highly effective in breast cancer development. Enhancer of zeste homolog 2 (EZH2) is an enzymatic epi-protein that takes part in most vital cell functions by its different action modes. EZH2 is suggested to be dysregulated in specific breast cancer types, particularly in advanced stages. Mounting evidence revealed that EZH2 overexpression or dysfunction affects the pathophysiology of breast cancer. In this review, we discuss biological aspects of the EZH2 molecule with a focus on its newly identified action mechanisms. We also highlight how EZH2 plays an essential role in breast cancer initiation, progression, metastasis, and invasion, which emerged as a worthy target for treating breast cancer in different approaches.
由于其高发生率和死亡率，乳腺癌已成为癌症领域的热门研究课题之一，在过去十年中，从各个方面进行了研究。表观遗传改变被认为在乳腺癌的发展中非常有效。EZH2（ Enhancer of zeste homolog 2）是一种酶性表观蛋白，通过不同的作用模式参与大多数重要的细胞功能。EZH2 被认为在特定的乳腺癌类型中失调，特别是在晚期。越来越多的证据表明，EZH2 过表达或功能障碍会影响乳腺癌的病理生理学。在这篇综述中，我们讨论了 EZH2 分子的生物学方面，重点是其新确定的作用机制。我们还强调了 EZH2 在乳腺癌的发生、发展、转移和浸润中所起的重要作用，这使其成为不同方法治疗乳腺癌的一个有价值的靶点。
